Biochemical and cellular effects of heparin-protamine injection in rabbits are partially inhibited by a PAF-acether receptor antagonist

European Journal of Pharmacology

Volumn 302, Issue 1-3, 1996, Pages 123-128

  Aïssa, Jamal ^a   Nathan, Nathalie ^b   Arnoux, Bernard ^a   Benveniste, Jacques ^a  

^a INSERM   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

BN 52021; Heparin; PAF (platelet activating factor); PAF acether; Platelet; Protamine; Thromboxane

Indexed keywords

GINKGOLIDE B; HEPARIN; INDOMETACIN; PROTAMINE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; THROMBOXANE B2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; HEMODYNAMICS; LEUKOCYTE COUNT; LEUKOPENIA; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTOPENIA;

EID: 0343725689     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00069-6     Document Type: Article

References (34)

1. Benveniste, J., 1988. Paf-acether an ether-phospholipid with biological activity, in: Biological Membranes, eds. M.L. Karnovsky, A. Leaf, L.C. Bolis (Alan R. Liss, New York) p. 73.
2. Benveniste, J., J.P. Le Couédic, J. Polonsky and M. Tencé, 1977, Structural analysis of purified platelet-activating factor by lipase, Nature 269, 170.
3. Benveniste, J., C. Boullet, C. Brink, and C. Labat, 1983, The actions of paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations, Br. J. Pharmacol. 80, 81.
4. Benveniste, J., D. Nunez, P. Duriez, R. Korth, J. Bidault and J.C. Fruchart, 1988. Preformed PAF-acether and lysoPAF-acether are bound to blood lipoproteins, FEBS Lett. 226, 371.
5. Best, N., B. Teisner, J.G. Grudzinskas and M.M. Fischer, 1983, Classical pathway activation during an adverse response to protamine sulfate, Br. J. Anaesth. 55, 1149.
6. Björk, J., L. Lindbom, B. Gerdin, G. Smedegaard, K.E. Arfors and J. Benveniste, 1983, Paf-acether increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds, Acta Physiol. Scand. 119, 305.
7. Camussi, G., C. Tetta, F. Bussolino, F. Caligaris Capio, R. Coda C. Masera and G. Segoloni, 1981, Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. Int. Arch. Allergy Appl. Immunol. 64, 25.
8. Cazenave, J.P., J. Benveniste and J.F. Mustard, 1979, Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane active drugs. Lab. Invest. 41, 275.
9. Chen, C.R., N.F. Voelkel and S.W. Chang, 1994, Platelet-activating factor potentiates protamine-induced lung edema, J. Respir. Crit. Care Med. 149, 34.
10. Conzen, P.F., H. Habazettl, R. Gutmann, J. Hobbhahn, A.E. Goetz, K. Peter and W. Brendel, 1989, Thromboxane mediation of pulmonary hemodynamic responses after neutralization of heparin by protamine in pigs, Anesth. Analg. 68, 25.
11. 2 release from the lung, Am. J. Surg. 154, 696.
12. Feuerstein, G. and R.E. Goldstein, 1987, Effect of paf on the cardiovascular system, in: Platelet-Activating Factor and Other Lipid Mediators, ed. F. Snyder (Raven Press, New York) p. 403.
13. Habazettl, H., P.F. Conzen, B. Vollmar, E. Yekebas, R. Gutmann, J. Hobbhahn, W. Brendel and K. Peter, 1990, Pulmonary hypertension after heparin-protamine: roles of left-sides infusion, histamine and platelet-activating factor. Anesth. Analg. 71, 637.
14. 2, J. Clin. Invest. 71, 351.
15. Hobbhahn, J., P. Conzen, B. Zenker, A.E. Goetz, K. Peter and W. Brendel, 1988, Beneficial effect of cyclooxygenase inhibition on adverse hemodynamic response after protamine. Anesth. Analg. 67, 253.
16. Jaques, L.B., 1949. A study of the toxicity of the protamine salmine, Br. J. Pharmacol. 4, 135.
17. Jastrzebski, J., P. Hilgard and M.K. Skyes, 1975. Pulmonary vasoconstriction produced by protamine and protamine-heparin complex in the isolated cat lung perfused with blood or dextran, Cardiovasc. Res. 9, 691.
18. Marin-Neto, J., M.K. Sykes, J.L.B. Marin, C. Orchard and M.K. Chakrabarti, 1979, Effect of heparin and protamine on left ventricular performance in the dog, Cardiovasc. Res. 13, 254.
19. 2, and prostacyclin, Pharmacol. Rev. 30, 293.
20. Montalescot, G., J.M. Mencia-Huerta, P. Braquet and M.Z. Warren, 1992, Role of platelet-activating factor in the ovine heparin-protamine reaction. J. Appl. Physiol. 73(6), 2604.
21. Montalescot, G., E. Kreil, K. Lynch, M. Greene, M. Torres, A. Carvalho, C. Fitzgibbon, D.R. Robinson, E. Lowenstein and W.M. Zapol, 1989. Effect of platelet depletion on lung vasoconstriction in heparin-protamine reactions, J. Appl. Physiol. 66, 2344.
22. Morel, D.R., E. Lowenstein, T. Nguyenduy, D.R. Robinson, J.E. Repine, D.E. Chenoweth and W.M. Zapol, 1988, Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep, Circ. Res. 62, 905.
23. Nathan, N., Y. Denizot, P. Feiss, E. Cornu, J. Benveniste and B. Arnoux, 1992, Variations in blood platelet-activating factor levels after protamine reversal of heparin in humans, Acta Anaesthesiol. Scand. 36, 264.
24. Nguyenduy, T., D.R. Morel and G. Collee, 1986, Acute pulmonary vasoconstriction induced by protamine reversal of heparin is mediated via generation of cyclooxygenase metabolites, Am. Rev. Resp. Dis. 133, 160.
25. Nunez, D., M. Chignard, R. Korth, J.P. Le Couedic, X. Norel, B. Spinnewyn, P. Braquet and J. Benveniste, 1986, Specific inhibition of paf-acether-induced platelet activation by BN 52021 and comparison with the paf-acether inhibitors Kadsurenone and CV 3988, Eur. J. Pharmacol. 123, 197.
26. Parsons, R.S. and K. Mohandas, 1989, The effect of histamine receptor blockade on the hemodynamic responses to protamine, J. Cardiothorac. Anesth. 3, 37.
27. Pinckard, R.N., J.C. Ludwig and L.M. McManus, 1988, Platelet-activating factor, in: Inflammation: Basic Principles and Clinical Correlates, eds J.I. Gallin, I.M. Goldstein, R. Snyderman (Raven Press, New York) p. 139.
28. Radegran, K. and McAslan, 1972, Circulatory and ventilatory effects of protamine-induced platelet aggregation and their inhibition by acetylsalicyclic acid. Acta Anesthesiol. Scand. 16, 76.
29. Robertson, D.N. and C.P. Page, 1987, Effect of platelet agonists on airway reactivity and intrathoracic platelet accumulation, Br. J. Pharmacol. 92, 105.
30. Schlondorff, D. and R. Neuwirth, 1986, Platelet-activating factor and the kidney, Am. J. Physiol. 20, 1.
31. Shaw, J.O., S.J. Klusick and D.H. Hanahan, 1981, Activation of rabbit platelet phospholipase and thromboxane synthesis by 1-O-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor), Biochim. Biophys. Acta 663, 222.
32. Smallbone, B.W., N.E. Taylor and J.W. McDonald, 1987, Effect of L-652,731. a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep, J. Pharmacol. Exp. Ther. 242, 1035.
33. Tencé, M., J. Polonsky, J.P. Le Couedic and J. Benveniste, 1980, Release. purification and characterization of platelet-activating factor (PAF), Biochimie 62, 251.
34. Wakefield, T.W., W.M. Whitehouse and J.C. Stanly, 1984, Depressed cardiovascular function and altered platelet kinetics following protamine sulfate reversal of heparin activity, J. Vasc. Surg. 1, 346.